Table 1.
Variable | All treated patients (n = 38) |
Type of TACE |
P value | |
DEB-TACE (n = 22) | c-TACE (n = 16) | |||
Age at LT (yr) | 56.5 ± 6.5 | 57.2 ± 6.5 | 55.6 ± 6.5 | 0.4545 |
Male gender | 34 (89.5) | 19 (86.4) | 15 (93.7) | 0.6245 |
MELD score | 10 (6-27) | 9 (6-27) | 10 (7-16) | 0.4688 |
Etiology of cirrhosis | 0.1834 | |||
HCV-related | 22 (57.9) | 10 (45.5) | 12 (75.0) | |
HBV-related | 11 (28.9) | 8 (36.3) | 3 (18.7) | |
Non-viral | 5 (13.2) | 4 (18.2) | 1 (6.3) | |
Waiting list time (mo) | 3.1 (0.1-26.7) | 2.9 (0.1-24.3) | 3.3 (0.6-26.7) | 0.5844 |
Interval between last TACE and LT (mo) | 3.6 (0.1-15.9) | 2.3 (0.2-13.8) | 5.5 (0.9-15.9) | 0.0625 |
Repeated TACE | 20 (52.6) | 12 (54.5) | 8 (50.0) | 0.7817 |
Adherence to MC at imaging before TACE | 0.3243 | |||
Within MC | 21 (55.3) | 14 (63.6) | 7 (43.7) | |
Beyond MC | 17 (44.7) | 8 (36.4) | 9 (56.3) | |
BCLC stage before TACE | 0.3243 | |||
A | 21 (55.3) | 14 (63.6) | 7 (43.7) | |
B | 17 (44.7) | 8 (36.4) | 9 (56.3) | |
Number of nodules before TACE | 2 (1-5) | 2 (1-5) | 2 (1-5) | 0.8708 |
Nodule number class before TACE | 0.2222 | |||
1 nodule | 16 (42.1) | 8 (36.4) | 8 (50.0) | |
1 < nodules < 4 | 13 (34.2) | 10 (45.4) | 3 (18.8) | |
Nodules ≥ 4 | 9 (23.7) | 4 (18.2) | 5 (31.2) | |
1Serum α-fetoprotein > 70 ng/mL | 8/33 (24.2) | 3/18 (16.7) | 5/15 (33.3) | 0.4811 |
Post-LT follow-up (mo) | 39.9 ± 22.5 | 34.9 ± 19.0 | 46.8 ± 25.6 | 0.1065 |
Continuous variables are reported as the mean and standard deviation or median and range and compared using Student’s t test or the Mann-Whitney U test as appropriate. Categorical variables are reported as numbers and percentages.
Value of serum α-fetoprotein was not available for 5 patients. TACE: Transcatheter arterial chemoembolization; DEB: Doxorubicin-eluting bead; MC: Milan Criteria; LT: Liver transplantation; HCV: Hepatitis C virus; HBV: Hepatitis B virus; MELD: Model for End Stage Liver Disease; c-TACE: Conventional TACE; BCLC: Barcelona Clinic Liver Cancer.